

## References

I-90

1. Orencia® (abatacept) package insert. Bristol-Myers Squibb Company, Princeton, NJ. 12/2011, Revised 04/2015.
2. Schiff M. Subcutaneous abatacept for the treatment of rheumatoid arthritis. *Rheumatology*. 2013;52(6):986-997.
3. Pieper J, Herrath J, Raghavan S, et al. CTLA4-Ig (abatacept) therapy modulates T-cell effector functions in autoantibody-positive rheumatoid arthritis patients. *BMC Immunology*. 2013;14:34.
4. Schiff M, Weinblatt M, Valente R, et al. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial. *Annals of Rheumatic Diseases*. 2013;203843.
5. Hanson R, Gannon M, Khamo N, et al. Improvement in safety monitoring of biologic response modifiers after the implementation of clinical care guidelines by a specialty pharmacy service in an academic health system. *Journal of Management Care Pharmacology*. 2013;19(1):49-67.
6. Alten R, Kaine J, Keystone E, et al. Long-term safety of subcutaneous abatacept in rheumatoid arthritis: Integrated analysis of clinical trial data representing more than four years of treatment. *Arthritis & Rheumatology*. 2014;66(8):1987–1997.
7. Nüßlein, H, Alten R, Galeazzi M, et al. Real-world effectiveness of abatacept for rheumatoid arthritis treatment in European and Canadian populations: A 6-month interim analysis of the 2-year, observational, prospective ACTION study. *BMC Musculoskeletal Disorders*. 2014;15:14.
8. Emery P, Burmester G, Bykerk V, et al. Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period. *Ann Rheum Dis*. 2015;74(1):19-26.
9. Schiff M. Subcutaneous abatacept for the treatment of rheumatoid arthritis. *Rheumatology (Oxford)*. 2013;52(6):986–997.
10. Rieke A, Kaine J, Keystone E, et al. Long-term safety of subcutaneous abatacept in rheumatoid arthritis: Integrated analysis of clinical trial data representing more than four years of treatment. *Arthritis Rheumatology*. 2014;66(8):1987–1997.
11. Tsuboi H, Matsumoto I, Hagiwara S, et al. Efficacy and safety of abatacept for patients with Sjögren's syndrome associated with rheumatoid arthritis: Rheumatoid arthritis with orencia Trial toward Sjögren's syndrome Endocrinopathy (ROSE) trial — an open-label, one-year, prospective study — Interim analysis of 32 patients for 24 weeks. *Modern Rheumatology*. 2015;25(2):187–93.
12. Ursini F, Russo E, Hribal M, et al. Abatacept improves whole-body insulin sensitivity in rheumatoid arthritis. *Medicine*. 2015;94(21):e888.
13. Singh J, Saag K, Bridges S, et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. *Arthritis Care & Research*. 2016;68(1):1-26.
14. Ringold S, Weiss P, Beukelman T, et al. 2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: Recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis

and tuberculosis screening among children receiving biologic medications. *Arthritis & Rheumatism*. 2013;65(10):2499-2512.

15. Keating G. Abatacept: A Review of its Use in the Management of Rheumatoid Arthritis. *Drugs*. 2013;73(10):1095-1119.
16. Smolen J, Wollenhaupt J, Westhovens R, et al. Attainment and characteristics of clinical remission according to the new ACR-EULAR criteria in abatacept-treated patients with early rheumatoid arthritis: new analyses from the Abatacept study to Gauge Remission and joint damage progression in methotrexate (MTX)-naive patients with Early Erosive rheumatoid arthritis (AGREE). *Arthritis Research & Therapy*. 2015;17:157.
17. Wells AF, Jodat N, Schiff M. A critical evaluation of the role of subcutaneous abatacept in the treatment of rheumatoid arthritis: patient considerations. *Bio Targ and Ther*. 2014;41-55.
18. Malaviya AP, Ostor AJK. Drug adherence to biologic DMARDS with a special emphasis on the benefits of subcutaneous abatacept. *Patient Prefer Adherence*. 2012;589-596.
19. Polinski JM, Kowal MK, Gagnon M, et al. Home infusion: safe clinically effective, patient preferred, and cost saving. *Healthcare*. 2016.
20. ASHP Guidelines on Home Infusion Pharmacy Services, 2013. Accessed September 2, 2017.
21. MICROMEDEX®SOLUTIONS Compendia. 2017. Abatacept.
22. Clinical Pharmacology Compendia. [database online]. Tampa FL: Gold Standard, Inc. Abatacept.